BioNTech (Mfg Services)
Mainz, DE · Marburg, DE
Hybrid — also manufactures internal programs
28 confirmed programs
· 11 sponsors
· Last scored 2026-10-29
82.1
Signal Score
○ FDA Inspections
✓ Clinical Trials (28)
✓ SEC Filings (97)
○ Press
✓ EMA GMP (8)
○ MHRA GMP
✓ HC GMP (2)
Quick Facts: BioNTech (Mfg Services)
- Signal Score
- 82.1/100 (as of 2026-10-29)
- Quality Compliance
- 100.0/100 — Clean EMA record: 8 active GMP certificates (no deductions)
- Headquarters
- Mainz, DE · Marburg, DE
- Modalities
- mRNA
- Active Programs
- 28 confirmed from ClinicalTrials.gov across 11 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About BioNTech (Mfg Services)
mRNA COVID vaccine manufacturer. Contract mfg capabilities.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
Clean EMA record: 8 active GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP
Clean EMA record: 8 active GMP certificates (no deductions)
FDA InspectionsNo US records on file
EMA GMP Certificates8 on record
Most Recent HC OutcomeCompliant · 2024-01-25
HC Attribution2 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean EMA record: 8 active GMP certificates (no deductions)
Operations
75.5
28 active programs across 11 sponsors
Modalities: mRNA
21 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
28 active programs across 11 sponsors · Modalities: mRNA · 21 programs in advanced phases (Phase 2/3)
Programs
28
Sponsors11
ModalitiesmRNA
28 active programs across 11 sponsors
Modalities: mRNA
21 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT06892548
A Clinical Study to Investigate the Efficacy and Safety of an...
PHASE1/PHASE2
Recruiting
View all 28 programs →
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability
83.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
97 SEC filings with industry mentions on record (shown, not scored)
SEC Filings97 with industry mentions (not scored)
Publicly traded — financial transparency
Capacity
58.0
3 manufacturing sites
Sites: Mainz, Germany, Marburg, Germany, Idar-Oberstein, Germany
Source: company profiles (manufacturing sites, modality breadth)
3 manufacturing sites
3 manufacturing sites
BioNTech (Mfg Services) EMA GMP Compliance 8 certificates
2025-10
2025-10
2025-10
2025-10
2025-10
2025-06
2024-09
2019-09
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| DE_RP_01_GMP_2025_0049 | BioNTech Innovative Manufacturing Services GmbH | Germany | 2025-10-23 | COMPLIANT |
| DE_RP_01_GMP_2026_0018 | BioNTech SE | Germany | 2025-10-01 | COMPLIANT |
| DE_RP_01_GMP_2026_0004 | BioNTech SE | Germany | 2025-10-01 | COMPLIANT |
| DE_RP_01_GMP_2026_0007 | BioNTech Manufacturing GmbH | Germany | 2025-10-01 | COMPLIANT |
| DE_RP_01_GMP_2026_0025 | BioNTech SE | Germany | 2025-10-01 | COMPLIANT |
| DE_RP_01_GMP_2026_0006 | BioNTech Manufacturing GmbH | Germany | 2025-06-17 | COMPLIANT |
| DE_HE_01_GMP_2025_0030 | BioNTech Manufacturing Marburg GmbH | Germany | 2024-09-04 | COMPLIANT |
| DE_RP_01_GMP_2020_0052 | BioNTech Manufacturing GmbH | Germany | 2019-09-11 | COMPLIANT |
Source: EMA EudraGMDP · Retrieved Nov 21, 2026
Clinical Activity 28 studies
NCT07361497
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent...
PHASE3
Recruiting
NCT07361510
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in...
PHASE3
Recruiting
NCT07111520
A Clinical Trial to Test if an Investigational Combination Therapy With...
PHASE1/PHASE2
Recruiting
NCT07070232
A Clinical Study to Test if an Investigational Treatment Called BNT326 is...
PHASE1/PHASE2
Recruiting
NCT06953089
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
PHASE2
Recruiting
NCT06940804
A Clinical Study Investigating the Therapeutic Effects and Safety of an...
PHASE2
Withdrawn
NCT06892548
A Clinical Study to Investigate the Efficacy and Safety of an...
PHASE1/PHASE2
Recruiting
NCT06841055
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational...
PHASE2
Recruiting
NCT06712355
Safety and Efficacy of BNT327, an Investigational Therapy in Combination...
PHASE3
Recruiting
NCT06750185
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy...
PHASE1/PHASE2
Recruiting
NCT06712316
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With...
PHASE2/PHASE3
Recruiting
NCT06616532
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as...
PHASE3
Active Not Recruiting
NCT06449209
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for...
PHASE2
Active Not Recruiting
NCT06046274
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced...
PHASE2
Withdrawn
NCT05914116
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
PHASE1/PHASE2
Recruiting
NCT05844150
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in...
PHASE2
Active Not Recruiting
NCT05557591
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With...
PHASE2
Active Not Recruiting
NCT05438329
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
PHASE1/PHASE2
Active Not Recruiting
NCT05142189
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy...
PHASE1
Recruiting
NCT05879068
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
PHASE2
Active Not Recruiting
+ 8 more studies
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Hiring Activity Beta
From public job postings on the parent company's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No open roles were listed at this business's sites on Nov 20, 2026.
Coverage: read from the parent company's careers board and kept only postings at this business's sites (BioNTech Innovative Manufacturing Services (Idar-Oberstein) on the BioNTech-wide board). Roles outside those sites are left out, and some of this unit's roles may be missed.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
jobs.biontech.com
· Checked Nov 20, 2026 · Tracking since Oct 26, 2026
Financial Intelligence
"gene therapy, that are perceived as similar to ours; and
–
the FDA or other regulatory authorities may require us to submit additional data, such as long-term toxicology"
"candidates, such as gene editing therapies, show encouraging results, potential trial participants and their"
"such entities, which include locally-based contract manufacturing organizations, or CMOs, and CROs, in the"
"contract manufacturing production capacities that become redundant or unutilized;
•
our expected revenues and net profit related to sales of our COVID-19 vaccine (also referred to as"
"write-downs and cancellations of contract manufacturing orders."
"operations;
•
continue to invest in our immunotherapy platforms to conduct research to identify novel technologies;
•
change our manufacturing capacity or capability;
•
change or add additional suppliers;
•
make changes to our infrastructure in connection with our quality control, quality assurance, legal,"
"Moreover, in support of the Company’s ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studies in patient populations for which product candidates are being developed in the Company’s respective clinical programs."
Source: SEC EDGAR · Retrieved Nov 21, 2026
Frequently Asked Questions About BioNTech (Mfg Services)
Does BioNTech (Mfg Services) hold EMA or MHRA GMP certificates?
CDMO Signal tracks 8 EMA GMP certificates for BioNTech (Mfg Services).
How many clinical programs is BioNTech (Mfg Services) linked to?
BioNTech (Mfg Services) is associated with 28 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is BioNTech (Mfg Services)'s CDMO Signal Score?
BioNTech (Mfg Services) has a Signal Score of 82/100, based on quality, operations, financial stability, and capacity data.
Evaluating BioNTech (Mfg Services) for a manufacturing program?
Use the free AI matchmaker to compare BioNTech (Mfg Services) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 90.1
Biologics, mRNA, Small Molecule API, Oral Solid Dose, High-Potency APIs, Sterile Fill-Finish
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 82.9
AAV, Lentiviral, Plasmid, mRNA
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
Signal Score: 82.9
Recombinant Protein, Plasmid DNA, mRNA, Microbial Fermentation
Compare BioNTech (Mfg Services) with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.